BioSpace News Archive

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results.

Their blood vessels develop abnormal shunts or holes that bypass the capillaries and could result in severe bleeding.

Intercept recorded $129.2 million of worldwide net Ocaliva sales for the full year 2017, and $37.3 million for the fourth quarter of 2017.

The SCOUT (Spineology Clinical Outcomes Trial) IDE, conducted under an FDA-approved protocol, is a prospective multicenter non-randomized performance goal investigation, designed to evaluate safety and effectiveness outcomes in instrumented lumbar interbody fusion procedures for the treatment of degenerative disc disease (DDD).

Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017.

The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.

This new approach moves the conjugation step into the later stages of the DSP, with conjugation and antibody purification carried out concurrently.

SCRS announced today that BMS has joined the organization as a Global Impact Partner.

The appointment increases the size of the Board of Directors to five members.

The study evaluated 2,189 cases that spanned 26 cancer types, of which 1,108 were colorectal cancer, to compare mismatch repair status of Caris’ NGS platform to the current industry standard of PCR-FA.